morphine extended release / Generic mfg. - LARVOL DELTA

Impact of Withdrawal of Extended-Release Morphine 5 mg on Hospital Analgesic Utilization. (PubMed, Basic Clin Pharmacol Toxicol) - No abstract available

Journal • Pain

Dual Thoracic and Cervical Spinal Cord Stimulation for Refractory Neuropathic Pain in Charcot-Marie-Tooth Disease: A Case Report (PAINWeek 2026) - "Conservative management, including extended-release morphine 30 mg every 8 hours and oxycodone/acetaminophen 10/325 mg every 6 hours, failed to provide adequate relief. The patient demonstrated substantial improvement in pain control following staged thoracic and cervical SCS implantation. Before SCS therapy, baseline pain intensity was rated as 10/10 on the VAS. Following the initial thoracic SCS placement, the patient reported reduction in pain severity ranging from 0-4/10 on serial follow ups."

Case report • Clinical • Addiction (Opioid and Alcohol) • CNS Disorders • Neuralgia • Pain • Peripheral Neuropathic Pain

Correlative Spectroscopic and Structural Imaging for Resin-Embedded Extended-Release Morphine Sulfate Pellets. (PubMed, AAPS PharmSciTech) - "This correlative workflow, combining resin embedding with multiple imaging modalities, underscores the value of LDIR and complementary techniques for comprehensive physicochemical characterization of complex drug products. These findings highlight the utility of correlative imaging for regulatory assessment and quality control of complex extended-release formulations."

Journal

Cough in Interstitial Lung Disease: Current Knowledge and Research Gaps. (PubMed, Pulm Ther) - "While antifibrotic therapies have shown limited and inconsistent effects on cough, recent randomized clinical trials provide encouraging evidence for low-dose morphine and extended-release nalbuphine in IPF-associated chronic cough. Several novel therapeutic strategies targeting neural and inflammatory pathways are currently under investigation. A better understanding of the mechanisms driving cough in ILD, together with standardized assessment tools and adequately powered clinical trials, will be essential to develop effective, disease-specific treatments for this disabling symptom."

Clinical • Journal • Review • Chronic Cough • Cough • Fibrosis • Gastroenterology • Gastroesophageal Reflux Disease • Idiopathic Pulmonary Fibrosis • Immunology • Inflammation • Interstitial Lung Disease • Obstructive Sleep Apnea • Pneumonia • Pulmonary Disease • Respiratory Diseases • Rheumatology • Sarcoidosis • Sleep Disorder

Local Multimodal Injection Versus Regional Anesthesia in Controlling Pain for Treating Rotational Ankle Fractures (clinicaltrials.gov) - P1 | N=200 | Active, not recruiting | Sponsor: University of Utah | Trial completion date: May 2026 ➔ May 2028 | Trial primary completion date: May 2026 ➔ May 2028

Trial completion date • Trial primary completion date • Anesthesia • Musculoskeletal Diseases • Orthopedics • Pain

Role of Multimodal Analgesia in Decreasing Perioperative Pain in Tibial Plateau Fractures (clinicaltrials.gov) - P1 | N=150 | Active, not recruiting | Sponsor: University of Utah | Trial completion date: Mar 2026 ➔ Mar 2028 | Trial primary completion date: Mar 2026 ➔ Mar 2028

Trial completion date • Trial primary completion date • Musculoskeletal Diseases • Orthopedics • Pain

SIFI: Symptom-inhibited Fentanyl Induction (clinicaltrials.gov) - P4 | N=48 | Completed | Sponsor: Pouya Azar | Recruiting ➔ Completed | Trial primary completion date: Dec 2024 ➔ Dec 2025

Trial completion • Trial primary completion date • Substance Abuse

Effectiveness of Percutaneous Neuromodulation vs Pharmacological Treatment in Cancer Patients With Anterior Knee Pain (clinicaltrials.gov) - P=N/A | N=0 | Withdrawn | Sponsor: Universidad Europea de Canarias | N=50 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Musculoskeletal Pain • Oncology • Pain

Application of OROS® Hydromorphone in cancer pain patients with poor analgesic effect of oxycodone hydrochloride sustained-release tablets (ChiCTR) - P=N/A | N=136 | Not yet recruiting | Sponsor: Peking Union Medical College Hospital, Chinese Academy of Medical Sciences; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

New trial • Oncology • Pain

Comparison of Hydromorphone Extended Release Tablets after Titration with Morphine in the Treatment of Cancer Pain (ChiCTR) - P=N/A | N=60 | Not yet recruiting | Sponsor: Kunming Yan 'an Hospital; Kunming Yan 'an Hospital

New trial • Oncology • Pain

The Role of a Palliative Care Support Team to Optimize Outcomes for Patients with Airway Involvement from Relapsing Polychondritis (ACR Convergence 2025) - "After an extended period of steroids and multiple medications, partial remission was achieved with low dose prednisone, IV tocilizumab, methotrexate, and hydroxychloroquine...Next, though I was skeptical, I start extended release morphine for air hunger...PC provides unique expertise in the treatment of respiratory symptoms and poor QOL commonly found in advanced stages of disease. Though traditionally associated with the end of life, when a PC team is utilized to focus on a patient's symptom control and QOL, it can help to optimize rehabilitation and maintenance of overall health thereby improving outcomes for patients with advanced airway involvement from RP."

Clinical • Asthma • Cough • Immunology • Infectious Disease • Mood Disorders • Obesity • Ocular Inflammation • Ophthalmology • Palliative care • Pulmonary Disease • Respiratory Diseases • Scleritis • Sjogren's Syndrome

Heroin consumption in patients referred to a consultation liaison addiction service in barcelona, Spain (ECNP 2025) - "At hospital discharge, a total of 436 patients (86.2%) were receiving methadone maintenance treatment, while a minority were on alternative therapies such as buprenorphine/naloxone (7 patients – 1.4%) or extended-release morphine (8 patients – 1.6%). Out of 3,408 patients admitted by the CLAS, 506 were heroin users. The mean age was 43.5 years (range: 19–80). Most of the patients were male (82.0%), and half of the patients (50.6%) were foreigners."

Clinical • Addiction (Opioid and Alcohol) • CNS Disorders • Depression • Mental Retardation • Mood Disorders • Psychiatry

Local Multimodal Injection Versus Regional Anesthesia in Controlling Pain for Treating Rotational Ankle Fractures (clinicaltrials.gov) - P1 | N=200 | Active, not recruiting | Sponsor: University of Utah | Enrolling by invitation ➔ Active, not recruiting

Enrollment closed • Anesthesia • Musculoskeletal Diseases • Orthopedics • Pain

Postoperative pain management for caesarean section in Denmark: A survey of current clinical practice. (PubMed, Acta Anaesthesiol Scand) - "Most Danish delivery centres relied on oral morphine in addition to NSAIDs and paracetamol for postoperative pain management following caesarean section. Use of truncal nerve blocks, wound infiltration and extended-release morphine showed many differences between centres. Intrathecal morphine was hardly used despite international recommendations due to the concern of side effects. A national research initiative (www.cepra.nu) will facilitate the evaluation of evidence and treatment options following caesarean section in Denmark."

Journal • Anesthesia • Obstetrics • Pain

Nanotechnology for Pain Management. (PubMed, J Clin Med) - "This formulation is the base of DepoDur™, which comprises a combination of liposomes and extended-release morphine, and Exparel™, which comprises a combination of liposomes and extended-release bupivacaine...The use of liposome led to the development of DepoDur™, bupivacaine Exparel™ and a mixture of bupivacaine and meloxicam (Zynrelef™) and more recently lidocaine liposome formulation... Increasing evidence supports the concept that nanotechnology may represent a valuable tool as a drug transporter including liposomes and as a nanocapacitor-based device/patch to reduce or even eliminate the use of opioids in surgical patients. However, more studies are required to confirm this concept, especially with the use of nanotechnology incorporated in devices/patches."

Journal • Review • Addiction (Opioid and Alcohol) • Gastroenterology • Orthopedics • Pain

SIFI: Symptom-inhibited Fentanyl Induction (clinicaltrials.gov) - P4 | N=50 | Recruiting | Sponsor: Pouya Azar | Not yet recruiting ➔ Recruiting

Enrollment open • Substance Abuse

Treatment of Poppy Seed Tea Dependence with Buprenorphine in a Telehealth Practice (ASAM 2024) - "Poppy seeds contain small amounts of alkaloids active on opiate receptors, including morphine, noscapine, papaverine and codeine (2)...However, individuals then have continued dependence to PST, which in turn can be treated with buprenorphine, methadone or a taper of extended-release morphine (5)...Describe the treatment trajectories and retention of patients treated with buprenorphine for poppy seed tea dependence in the telehealth setting. Discuss the typical doses of buprenorphine needed to treat patients with poppy seed tea dependence."

Addiction (Opioid and Alcohol) • Substance Abuse

The Dose-Response Relationship between Opioid Agonist Therapy and Alterations in Pain Pathways in Patients with Opioid Use Disorders: A Cross-Sectional Study. (PubMed, CNS Drugs) - "The present trial demonstrates the clear effects of opioid agonist therapy on the somatosensory system. Both central sensitization and descending pain modulation are negatively affected by high doses of opioids and our data elucidate a moderate dose-response relationship for these phenomena."

Journal • Observational data • Addiction (Opioid and Alcohol) • Pain • Substance Abuse

Effectiveness of Percutaneous Neuromodulation vs Pharmacological Treatment in Cancer Patients With Anterior Knee Pain (clinicaltrials.gov) - P=N/A | N=50 | Not yet recruiting | Sponsor: Universidad Europea de Canarias

New trial • Musculoskeletal Pain • Oncology • Pain

SIFI: Symptom-inhibited Fentanyl Induction (clinicaltrials.gov) - P4 | N=50 | Not yet recruiting | Sponsor: Pouya Azar | Trial completion date: Jul 2025 ➔ Dec 2025 | Initiation date: Jul 2023 ➔ Jan 2024 | Trial primary completion date: Jul 2024 ➔ Dec 2024

Trial completion date • Trial initiation date • Trial primary completion date • Substance Abuse

Outpatient Rapid Titration of Slow Release Oral Morphine for the Treatment of Opioid Use Disorder in a Canadian Setting: A Case Series. (PubMed, J Addict Med) - "In the cases described, substantial reductions in unregulated fentanyl use and social gains, such as obtaining housing, employment, and enrollment in inpatient treatment programs, were observed after rapid SROM titration. No overdoses occurred during rapid SROM titration or during SROM treatment. More research is needed to determine the role for rapid SROM titrations as a stabilization option for outpatients."

Journal • Addiction (Opioid and Alcohol) • CNS Disorders • Substance Abuse

Assessing the impact of the slow-release oral morphine drug shortages in Ontario, Canada: A population-based time series analysis. (PubMed, Int J Drug Policy) - "The SROM-24 shortages resulted in significant treatment disruptions across all recipients. These findings have important implications for those with few treatment alternatives, including people using SROM-24 as OAT who are at risk of adverse outcomes following treatment disruptions."

Journal • Pain • Substance Abuse

SIFI: Symptom-inhibited Fentanyl Induction (clinicaltrials.gov) - P4 | N=50 | Not yet recruiting | Sponsor: University of British Columbia

New P4 trial • Substance Abuse

Local Multimodal Injection Versus Regional Anesthesia in Controlling Pain for Treating Rotational Ankle Fractures (clinicaltrials.gov) - P1 | N=200 | Enrolling by invitation | Sponsor: University of Utah | Trial completion date: May 2023 ➔ May 2026 | Trial primary completion date: May 2023 ➔ May 2026

Trial completion date • Trial primary completion date • Anesthesia • Musculoskeletal Diseases • Orthopedics • Pain

Role of Multimodal Analgesia in Decreasing Perioperative Pain in Tibial Plateau Fractures (clinicaltrials.gov) - P1 | N=150 | Active, not recruiting | Sponsor: University of Utah | Enrolling by invitation ➔ Active, not recruiting | Trial completion date: Mar 2023 ➔ Mar 2026 | Trial primary completion date: Mar 2023 ➔ Mar 2026

Enrollment closed • Trial completion date • Trial primary completion date • Musculoskeletal Diseases • Orthopedics • Pain